PATENT

Docket No.: 2026-4269PC

IN THE EUROPEAN PATENT OFFICE (ISA/EP)

Applicant

The Government of the United States of America, as

represented by the Secretary, Department of Health and Human

Services et al

International

Application No.:

PCT/US98/19609

International

Filing Date

21 September 1998 (21.09.1998)

For

NOVEL HUMAN CANCER ANTIGEN

ESO-1/CAG-3 AND GENE ENCODING SAME

VIA FACSIMILE ORIGINAL VIA DHL COURIER

International Searching Authority
European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Netherlands

Attn: Mirella Deleye-Milani

STATEMENT UNDER RULE 27A(2) AND Rule 27a(3) AND 37 C.F.R. §1.821(f) and (g)

In compliance with Rule 27a(2) EPC and 37 C.F.R. §1.821(f),

Applicants submit that the information recorded on the electronic data carrier is identical to the written sequence listing; and in compliance with Rule 27a(3) EPC and 37 C.F.R. §1.821(g), that the sequence listing documents do not include matter which goes beyond the content of the PCT application as filed.

PATENT.

Docket No.: 2026-4269PC

Applicants believe that this statement complies with WIPO Standard

ST.23.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: 26 January 1999

By:

Agent for Applicants Kathryn M. Brown

MORGAN & FINNEGAN, L.L.P. 345 Park Avenue New York, New York 10154 (212)758-4800 TELEPHONE (212)751-6849 (FAX)